1 as crystallized, both free and with bound 3'-uridine monophosphate (3'-UMP).

2 ted into aspartate (a nucleotide precursor), uridine monophosphate (a precursor of pyrimidine nucleos

3 l formyltransferase domain in a complex with uridine monophosphate and N-5-formyltetrahydrofolate.

4 ructures of DT in complex with adenyly(3'-5')uridine monophosphate (ApUp) and DT in complex with nico

5     Moreover, the presence of several umami (uridine monophosphate, inosine monophosphate, adenosine,

6 orotate phosphoribosyltransferase, 2.3-fold; uridine monophosphate kinase, 3.2-fold; pyrimidine nucle

7 ng allosteric and substrate binding sites of uridine monophosphate kinase, and suggested that in solu

8 gulation of the near-terminal pathway enzyme uridine monophosphate kinase.

9 the genome, we determined that the conserved uridine monophosphate phosphoribosyltransferase (UMPS),

10     We find that uric acid directly inhibits uridine monophosphate synthase (UMPS) and consequently r

11  and selected against, such as deficiency of uridine monophosphate synthase, complex vertebral malfor

12                                              Uridine monophosphate (UMP) kinase is a conserved enzyme

13 ated 5'-adenosine monophosphate (AMP) and 5'-uridine monophosphate (UMP) molecules confined in multi-

14 T3Gal-II also catalyzed the conversion of 5'-uridine monophosphate (UMP) to UMP-NeuAc, which was foun

15 ntrations of inosine monophosphate (IMP) and uridine monophosphate (UMP) were only 30% of those found

16 showcase our workflow by annotating N-methyl-uridine monophosphate (UMP), lysomonogalactosyl-monopalm

17 e that catalyzes the conversion of uracil to uridine monophosphate (UMP).

18                         Mixtures composed of uridine monophosphate, uridine diphosphate, uridine trip

19 eads to build-up of the pathway intermediate uridine monophosphate, which is in turn degraded by a co